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Abstract In this study we demonstrate the added value of mathematical model
reduction for characterizing complex dynamic systems using bone remodeling as an
example. We show that for the given parameter values, the mechanistic RANK-
RANKL-OPG pathway model proposed by Lemaire et al. (J Theor Biol
229:293–309, 2004) can be reduced to a simpler model, which can describe the
dynamics of the full Lemaire model to very good approximation. The response of
both models to changes in the underlying physiology and therapeutic interventions
was evaluated in four physiologically meaningful scenarios: (i) estrogen deficiency/
estrogen replacement therapy, (ii) Vitamin D deficiency, (iii) ageing, and (iv) chronic
glucocorticoid treatment and its cessation. It was found that on the time scale of
disease progression and therapeutic intervention, the models showed negligible
differences in their dynamic properties and were both suitable for characterizing the
impact of estrogen deficiency and estrogen replacement therapy, Vitamin D defi-
ciency, ageing, and chronic glucocorticoid treatment and its cessation on bone
forming (osteoblasts) and bone resorbing (osteoclasts) cells. It was also demonstrated
how the simpler model could help in elucidating qualitative properties of the
observed dynamics, such as the absence of overshoot and rebound, and the different
dynamics of onset and washout.
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Introduction
The objective of disease system analysis is to characterize and predict the status of
biological systems under physiological and pathophysiological conditions as well as
the impact of therapeutic interventions [1–3]. Models characterizing this dynamic
behavior can be established at different levels of complexity, ranging from data
driven and descriptive to completely mechanistic approaches (systems pharmacol-
ogy) [3, 4]. Descriptive approaches usually start at a clinical observation level and
become increasingly more complex in order to understand the system better,
whereas systems pharmacology approaches start at the molecular level and provide
a full description of the pathways involved. While descriptive models may not
predict the clinical response beyond the data on which they were established,
completely mechanistic approaches may face problems with the identifiability of
model parameters [3, 4]. To obtain a sufficient understanding of a biological system,
its dynamics, and the impact of therapeutic interventions, a compromise between the
descriptive and the systems approach is frequently needed. This compromise results
in mechanisms-based disease system models, which strive to characterize a system’s
behavior rather than its complexity [5].
One important challenge to be met when developing mechanism-based disease
system models is the appropriate handling of the different time scales present in
biological systems. While processes on the molecular level, such as receptor binding
or enzymatic reactions, are usually fast (within milliseconds), it can take months or
even years before clinical signs and symptoms of chronic, progressive diseases
become manifest. The design of mechanism-based disease system models conse-
quently relies on a sufficient understanding of the relative speeds of the underlying
(patho)physiological processes. Acquiring this information requires familiarity with
various mathematical analysis techniques including dimensional analysis, dynam-
ical systems analysis, and mathematical model reduction approaches (i.e., singular
perturbation theory (see, e.g. [6]). When applying these techniques for the analysis
of complex dynamic systems, the relative importance and speed of the different
processes involved can be determined. Information on the system’s dynamic
properties thus obtained can then be used to derive simpler models. Such reduced
models yield dynamic properties that are very similar to those of completely
mechanistic models but require the identification of fewer parameters. They also
yield important insights into the impact of different parameters on the full system
and often explicit expressions and quantitative estimates for drug-, system-, and/or
disease-specific characteristics, such as clearance or the area under the curve of
different compounds [6, 7].
The objective of this article is to demonstrate the added value of mathematical
model reduction for establishing mechanism-based disease system models, using
bone remodeling as an example. Bone remodeling is a physiological process that
allows continuous renewal and repair of bone structure [8]. It is accomplished by
874 J Pharmacokinet Pharmacodyn (2011) 38:873–900
123
groups of osteoblasts (bone forming cells) and osteoclasts (bone resorbing cells),
which closely collaborate in so-called basic multicellular units (BMU) [9, 10]. The
interaction between osteoblasts and osteoclasts is highly regulated and provides
the basis for a temporally and spatially coordinated bone remodeling process.
Disturbances in the regulation of these cell–cell interactions can result in
pathophysiological conditions, such as osteoporosis [11].
The RANK-RANKL-OPG signaling pathway is one of the key players involved in
the osteoblast-osteoclast regulation [12]. This regulatory pathway consists of three
main components: (i) the receptor activator of nuclear factor jB (RANK), which is
expressed on the surface of osteoclasts, (ii) the RANK ligand (RANKL), a
polypeptide expressed on the surface of osteoblasts, and (iii) osteoprotegerin (OPG),
a soluble decoy receptor for RANKL released by osteoblasts [12]. To date, multiple
conceptual bone cell interaction models have been established [10, 13–18] some of
which specifically incorporate the RANK-RANKL-OPG pathway [10, 13, 16]. Of
these conceptual frameworks, Lemaire et al. were the first to propose a model, where
the interaction between the different types of bone cells within a BMU (responding
osteoblasts (R), active osteoblasts (B), and active osteoclasts (C)) is mediated by the
RANK-RANKL-OPG regulatory pathway [13].
It will be shown how the mechanistic bone cell interaction model proposed by
Lemaire et al. [13] may be mathematically reduced for the parameter values quoted
in [13] and for physiologically and therapeutically relevant time scales. The
dynamic properties of the full and the reduced model will then be compared using
simulations, in which the response of both models to changes in physiological states
and/or therapeutic interventions will be evaluated using physiologically meaningful
scenarios. Estrogen (deficiency and replacement therapy) will be used as the
primary example. In addition, the effects of Vitamin D, ageing, and chronic
glucocorticoid treatment on the bone cell dynamics will be evaluated. The reduced
model will then be used to obtain answers to questions about qualitative properties
of response curves, such as the possibility of overshoot and rebound. Finally, we
will conclude with a discussion of the advantages and limitations of mathematical
model reduction as well as its implications for clinical situations.
Materials and methods
In the conceptual bone cell interaction model proposed by Lemaire et al. [13], both
the osteoblastic and the osteoclastic cell line consist of cells at different levels of
maturation (cf. Fig. 1). Responding osteoblasts (R) are recruited from a large pool of
uncommitted osteoblast progenitor cells (Ru), which then differentiate into active,
bone-forming osteoblasts (B). Active, bone-removing osteoclasts (C), on the other
hand, are recruited from a pool of osteoclast progenitor cells (CP) upon stimulation
of RANK by its ligand. In addition to this receptor-mediated osteoblast-osteoclast
interaction, a number of local and systemic hormones play a role in the regulation of
bone remodeling. Of these factors, transforming growth factor beta (TGF-b) and
parathyroid hormone (PTH) have been incorporated into the Lemaire model [13].
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TGF-b is released from the bone by active osteoclasts and promotes multiple
mechanisms of action: (1) it stimulates the recruitment of responding osteoblasts,
(2) it inhibits the differentiation of responding osteoblasts into active osteoblasts,
and (3) it stimulates the apoptosis of active osteoclasts. PTH, on the other hand,
promotes its effect on osteoblasts and osteoclasts through the RANK-RANKL-OPG
pathway, where it stimulates the expression of RANKL and suppresses the secretion
of OPG.






















where DR represents the differentiation rate of osteoblast progenitors, DB the
differentiation rate of responding osteoblasts, DC the differentiation rate of
osteoclast precursors, pC(C) the TGF-b receptor occupancy, and pL(R,B) the
RANK receptor occupancy. While pC(C) is dependent on the amount of TGF-b
Fig. 1 Schematic illustration of the bone-cell interaction model. Ru uncommitted osteoblast progenitor,
R responding osteoblast, B active osteoblast responsible for bone formation, Cp osteoclast progenitor,
C active osteoclast responsible for bone resorption, PTH parathyroid hormone, TGF-b transforming
growth factor-b, OPG osteoprotegerin, RANK receptor activator of NF-jB, RANKL receptor activator of
NF-jB ligand. RANK-RANKL-OPG regulatory pathway: RANKL binds to RANK and promotes
osteoclast differentiation, while OPG inhibits this differentiation by binding RANKL. Definitions and
values of the rate constants are provided in Tables 1 and 2. This figure and its legend are taken from Ref.
[13] and were slightly modified
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released from bone by active osteoclasts, pL(R,B) is determined by the amount of
RANKL attached to the surface of active osteoblasts (KL
P) and the OPG production
rate of responding osteoblasts (KO
P) as shown in Eqs. 2–4.
Since binding of TGF-b to its receptor is faster than any changes in the active
osteoclast population, pC(C) can be expressed as a function of C, i.e.
pCðCÞ ¼ C þ f0C
s






0 \f0\1ð Þ ð2Þ
where f0 equals the minimum receptor occupancy and C
s is half the value of C
necessary to obtain maximum TGF-b receptor occupancy (cf. Eq. 2). For the
dependence of pL on R and B we have the expression,
pLðR; BÞ ¼ aB
1 þ bR a[ 0; b [ 0ð Þ ð3Þ
where a and b can be computed from equation (4) in which pP represents the
fraction of occupied PTH receptors,
a ¼ k3
k4 þ k3K K
P








The impact of changes in the underlying physiology or therapeutic interventions is
reflected in changes of some of the parameters in Eqs. 1–4. Specifically, estrogen
affects KPO and hence b, Vitamin D affects pP and hence a and b, ageing affects C
s
and hence pC Cð Þ, and glucocorticoid treatment affects DR. As a result, physiological
processes and therapeutic interventions will cause these parameters to change with
time (cf. Evaluation of model behavior).
We assume that initially, the values of all the parameters are those given by
Lemaire et al. [13] (cf. Table 1), and that the system starts from the baseline values
R0, B0, and C0 for those parameters:
Rð0Þ ¼ R0; Bð0Þ ¼ B0; Cð0Þ ¼ C0: ð5Þ
Plainly, R0, B0, and C0 satisfy the algebraic equations
DRpCðC0Þ  DBpCðC0ÞR0 ¼ 0
DB
pCðC0ÞR0  kBB0 ¼ 0
DC
aB0











in which the parameters that change with time are taken at their initial values, i.e.,
their values at time t = 0. The respective values of the parameters used in Eqs. 1–6,
as given by Lemaire et al. [13], are presented in Table 1. Numeric values for the
baseline concentrations are computed in Appendix A:
R0 ¼ 1:82  104 pM; B0 ¼ 1:58  103 pM; C0 ¼ 3:285  103 pM: ð7Þ
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Mathematical model reduction
When attempting to gain insight into the dynamics of the system of Eq. 1 and
identify its characteristic properties, it is important to assess the relative importance
of the individual terms in the three equations and the relative speed and time scales
of the different processes involved. In order to do so, we cast the system into
dimensionless form. Using the baseline values R0, B0 and C0 as reference values for
the concentrations, we put
x ¼ R
R0
; y ¼ B
B0
; z ¼ C
C0
ð8Þ
and we introduce the dimensionless function related to pC(C):
pzðzÞ ¼ z þ f0z
s





Table 1 Parameter values provided by Lemaire et al. [13]
Symbol Unit Value Description
DR pM day
-1 7 9 10-4 Differentiation rate of osteoblast progenitors
DB day
-1 0.7 Differentiation rate of responding osteoblasts
kB day
-1 0.189 Elimination rate of active osteoblasts
DC pM day
-1 2.1 9 10-3 Differentiation rate of osteoclast precursors
DA day
-1 0.7 Osteoclast apoptosis rate due to TGF-b
f0 Dimensionless 0.05 Positive constant characterizing the minimum TGF-b receptor
occupancy
Cs pM 5 9 10-3 About half the value of C to get maximum TGF-b receptor
occupancy
k1 pM
-1 day-1 10-2 Rate of OPG-RANKL binding
k2 day
-1 10 Rate of OPG-RANKL dissociation
k3 pM
-1 day-1 5.8 9 10-4 Rate of RANK-RANKL binding
k4 day
-1 1.7 9 10-2 Rate of RANK-RANKL dissociation
k5 pM
-1 day-1 0.02 Rate of PTH binding to its receptor
k6 day
-1 3 Rate of PTH dissociation from its receptor
K pM 10 Fixed concentration of RANK
KL
P pM/pM cells 3 9 106 Maximum number of RANKL attached to the cell surface of
each active osteoblast
kO day




2 9 105 Minimum OPG production rate per responding osteoblast
IP pM day
-1 0 Rate of PTH administration
SP pM day
-1 250 Rate of PTH synthesis
kP day
-1 86 Rate of PTH elimination
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and the baseline is given by
xð0Þ ¼ yð0Þ ¼ zð0Þ ¼ 1: ð11Þ
For the sake of transparency, we derive the Reduced Model for the estrogen
scenario, where b is the only parameter that changes with time, i.e. b = b(t). We
denote the initial value of b by b0, i.e. b(0) = b0, and write
bðtÞ ¼ b0f ðtÞ; where f 0ð Þ ¼ 1: ð12Þ
For the other scenarios we obtain the same Reduced Model. For these scenarios
the derivation is very similar and we shall not reproduce it here.
We use the three equations in (6) to eliminate the baseline concentrations B0 and














¼ DApzð1Þ  1 þ b0R0














where pz(1) is the baseline value of pz(z).
To complete the transformation to dimensionless variables, it remains to make
the independent variable, time, dimensionless as well. This involves selecting a
characteristic time scale for the system (13). Since the elimination rate of y or B is
given by kB, with a corresponding half-life of ln(2)/kB, a characteristic time scale
















¼ l 1 þ b0R0












with f ðsÞ ¼ f ðtÞ ð15Þ
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where we have introduced the dimensionless numbers:
e ¼ kB
DB
pzð1Þ and l ¼ DA
kB
pzð1Þ: ð16Þ
For the parameter values used by Lemaire et al. [13] (cf. Appendix A), we obtain
e = 0.11 and l = 1.58. The small value of e, relative to the other coefficients in the
system, implies that x(s) rapidly converges to a zero of the right hand side of the first
equation of (15), while z(s) changes only slowly. Thus, after a brief initial period,
x(s) and z(s) are to good approximation related by the equation
rðzÞ  x
rðzÞ ¼ 0 ð17Þ
i.e., x and z are in quasi-equilibrium or quasi-steady state. For more details of this
‘‘quasi-steady state approximation’’ we refer to [6, 7, 19, 20].
Equation 17 can now be used to eliminate x from the second and third equation
of the system (13) and so to obtain a simpler system, which only involves the
dimensionless concentrations y and z:
dy
ds
¼ rðzÞ  y
dz
ds
¼ l 1 þ b0R0



























obtained by equating the right-hand side of the first equation in (1) to zero.
Thus, we have shown that for the parameter values used in Lemaire et al. [13],
after a brief initial period we may put the right-hand side of the equation for dR/dt to
zero and use the resulting equation to express R in terms of C, which allows one to
reduce the original system involving the three dependent variables R, B, and C
to one of two with the dependent variables B and C. We refer to the latter system as
the Reduced System.
For the other three scenarios we arrive at the same Reduced System (19) and (20).
However, different parameters may vary with time. Thus, in the Vitamin D scenario,
both a and b vary with time, in the ageing scenario it is pc(C) that changes and in the
glucocorticoid scenario DR changes with time.
The reduced system (19), is of a type recently discussed by Zumsande et al. [21].
However, in their study they focused on the stability of steady states. As we shall
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see, this is no issue in our study because for the parameter values from Lemaire
et al. the baseline is stable, and remains so when it slowly changes under the impact
of disease progression and therapeutic interventions.
Reduction to a two-dimensional system opens the way for a transparent
discussion of its dynamics. The state of a system at a given time t, is given by the
pair (B(t), C(t)), which can be represented by a point in the (B, C)-plane (in terms of
dimensionless variables this is the (y, z)-plane), often referred to as the Phase
Plane. In Appendix B we describe how the state (B(t), C(t)) moves through the
phase plane as time progresses and show what information about the system we can
derive from it.
Evaluation of the model behavior
To evaluate the dynamic properties of both models, the four physiologically
meaningful scenarios outlined by Lemaire et al. [13] (estrogen deficiency, Vitamin
D deficiency, ageing, and chronic glucocorticoid treatment) were used for
simulations. Simulation parameters are provided in Table 2. It should be noted
Table 2 Simulation parameters
Scenario Parameter Unit Value Description
Estrogen b0 pM
-1 21985 Value of b at time zero
Imax Dimensionless 0.9994 Maximum inhibition of OPG production
kdis day
-1 0.0015 Rate at which estrogen production
declines
kint day
-1 0.015 Rate at which estrogen production
increases during estrogen replacement
therapy
Db pM-1 3000 Maximum increase in b
Vitamin D a0 pM
-1 1479 Value of a at time zero
a1 pM
-1 1460 Maximum value of a at maximum
deficiency (6 months)
b0 pM
-1 21985 Value of b at time zero
b1 pM
-1 22274 Value of b at maximum deficiency
(6 months)
Ageing C0
s pM 5 9 10-3 Value of Cs at time zero
k Dimensionless 5.5 Factor by which Cs increases
kage day
-1 6 9 10-4 Rate at which Cs increases
Glucocorticoids DR(0) pM day
-1 7 9 10-4 Differentiation rate of osteoblast
progenitors at time zero
DR(?) pM day
-1 1.7 9 10-4 Differentiation rate of osteoblast
progenitors at time infinity
kdis day
-1 7.8 9 10-4 Rate of onset of glucocorticoid-induced
side effects
kwash day
-1 7.8 9 10-3 Rate at which glucocorticoid-induced side
effects wash out
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that estrogen deficiency, Vitamin D deficiency, and ageing characterize changes in
physiological states, whereas chronic glucocorticoid treatment leads to drug-
induced side effects.
Estrogen
Estrogen promotes its action, at least in part, through the RANK-RANKL-OPG
pathway by stimulating the production of OPG [13]. As estrogen production
increases significantly during menarche, the RANKL/OPG ratio decreases resulting
in a relative decrease in osteoclast activity leading to a substantial increase in
longitudinal and radial bone growth as well as rapid skeletal mineralization [22]. On
the other hand, a decrease in estrogen production by 85–90% during menopause
results in rapid bone loss and subsequently in an increased risk of bone fracture [22].
The decrease in estrogen production during menopausal transition does not occur
instantaneously but slowly evolves over a period of several years.
For this analysis, it was assumed that the main decrease in estrogen production
takes place during early post menopause over a period of 5 years [23]. It is further
assumed that this decrease in estrogen corresponds to a decrease of the OPG
production rate (KO
P) [8]. It was assumed for this simulation that KO
P decreases from
2 9 105 pM day-1/pM cells to 158 pM day-1/pM cells [13], resulting in a
corresponding drop in b (cf. (4)). We assume a mono-exponential decline of b
over a period of 5 years (which corresponds to a t1/2 of 1.25 years and
kdis = 0.0015 day
-1),
bðtÞ ¼ bbasðtÞ ¼ b0 1  Imax 1  ekdist
   ð21Þ
where bbas(0) = b0 is the initial baseline value and bbas(?) = b0(1-Imax) with
Imax = 0.9994 as the maximum inhibition of OPG production.
The increasing lack of endogenous estrogen in post-menopausal women can be
compensated for by supplying exogenous estrogen (hormone replacement therapy).
Studies have shown that hormone replacement therapy is usually well tolerated by
women during the first few years of treatment, whereas the risk for cardio vascular
disease, stroke, venous thromboembolic events and possibly breast cancer is
increased after more than 5 years of treatment [24–26]. For this analysis, treatment
with estrogen was started 1 year post menopause and continued for 3 years.
Respective changes in bone cell populations were simulated using Eq. 22 to account
for the natural decline in estrogen production as well as the effect of hormone
replacement therapy on the OPG production rate,
bðtÞ ¼ bbasðtÞ þ bintðtÞ ð22Þ
where bbas(t) is the baseline value of b as it evolves with time, given by (21), and
bint(t) the change in b caused by the therapeutic intervention. An additive term was
used for characterizing the therapeutic intervention, where the loss of endogenous
estrogen is balanced by a supply of exogenous estrogen:
bintðtÞ ¼ Db 1  ekint tt1ð Þ
 	
 H t  t1ð Þ½   1  ekint tt2ð Þ
 	
 H t  t2ð Þ½ 
n o
: ð23Þ
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In this equation, Db represents the maximum increase in b due to estrogen
replacement, kint the rate at which the corresponding OPG production increases, t1 the
time at which treatment with exogenous estrogen starts, t2 the time at which treatment
is discontinued (t1 = 1 year and t2 = 4 years), and H the Heaviside function.
1
Vitamin D
Vitamin D plays an important role in maintaining the body’s calcium and phosphate
homeostasis and is consequently important for the formation as well as the
maintenance of bone [27]. While recent morphogenetic studies also suggest a direct
effect on the osteoblastic phenotype expression [28], Vitamin D promotes its main
effect on bone by regulating PTH levels and thus the RANKL/OPG ratio. At
physiological levels, Vitamin D decreases the synthesis and secretion of PTH [29] as
well as the number of PTH receptors [30, 31] resulting in a decrease in RANKL
expression and an increase in OPG secretion. In case of Vitamin D deficiency, this
inhibiting effect on PTH diminishes leading to an increased RANKL/OPG ratio and
increased bone resorption.
Calcitriol, the bioactive form of Vitamin D, is formed from mainly two
biologically inert precursors, cholecalciferol and ergocalciferol, via biotransforma-
tion in the liver and the kidneys [27]. Cholecalciferol is formed in the skin when
7-dehydrocholesterol is exposed to ultraviolet B light (UVB, 290–320 nm), whereas
ergocalciferol is produced by plants and taken up by diet. Assuming that the dietary
intake of ergocalciferol does not significantly change during the course of 1 year,
changes in Vitamin D levels, and thus changes in bone mineral density, are
correlated with seasonal differences in sunlight exposure [32].
For this analysis, it was assumed that these seasonal differences in Vitamin D












where SP,min = 250 pM/day is the normal value and SP,max = 3765 pM/day is the
value characterizing maximal Vitamin D deficiency (cf. Lemaire et al.). If no
additional PTH is administered, the PTH receptor occupancy pP is proportional to
SP (cf. (Appendix A, Eq. 28)) This fluctuation in SP results in periodic changes in
the values of a and b.
Ageing
Ageing is associated with significant bone loss in both men and women [33]. The
extent of this loss can differ between the different bone sites and has been associated
with a decrease in TGF-b production as well as its release from bone [34–36]. Once
TGF-b levels decrease, their stimulating effect on osteoclast apoptosis decrease
resulting in increased osteoclast activity and increased bone resorption. In addition,
1 The Heaviside function H(s) is defined as follows: H(s) = 0 for s \ 0 and H(s) = 1 for s [ 0. Thus, for
any time T [ 0, H(t-T) = 0 for t \ T and H(t-T) = 1 for t [ T.
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the differentiation of OPG-secreting responding osteoblasts to RANKL-expressing
active osteoblasts is no longer inhibited. This gradual loss of regulatory feedback
leads to an increased RANKL/OPG ratio and further stimulation of osteoclasts.
The age-dependent loss of the bone’s TGF-b content was modeled by Lemaire et al.
[13] by decreasing the value of pC(C) by a factor of 5.5. However, pC(C) is a non-linear
function, which depends on C, f0, and C
s as shown in Eq. 2. Decreasing this function by
a constant factor does consequently require additional assumptions. For this analysis,
it was assumed that the decrease in pC is caused by an increase in C
s (about half the
value of C necessary to obtain maximum TGF-b receptor occupancy) since more bone
needs to be resorbed to yield the same amount of TGF-b. It was further assumed that
these age-dependent changes in TGF-b become clinically relevant for individuals
aged 65 and older and manifest themselves over a period of approximately 12.5 years
(average life expectancy in Western World: 75–80 years). The change of the bone’s
TGF-b content over time (Cs(t)) can be computed according to Eq. 25,




s represents the bone’s TGF-b content at the age of 65, kage the rate and
k[ 1 the extent by which Cs increases in the elderly.
Glucocorticoids
Bone loss and increased fracture risk due to long-term glucocorticoid therapy is the
most common cause of drug-induced osteoporosis [37]. The extent of this drug-
induced side effect seems to be dependent on the cumulative glucocorticoid dose
and affects trabecular bone more than cortical bone [37, 38]. Although glucocor-
ticoid receptors are present in almost every vertebrate cell, glucocorticoids seem to
primarily affect bone formation by decreasing the expression of osteoblastic
differentiation factors, such as core binding factor A1 [39–41].
Glucocorticoid-induced effects on bone were modeled by Lemaire et al. [13] by
decreasing the differentiation rate of osteoblast progenitors (DR). Since these drug-
related adverse effects only emerge after a chronic treatment with glucocorticoids, it
was assumed for this simulation that DR decreases slowly from 7 9 10
-4 to
1.7 9 10-4 pM/day at a rate kdis over 5 years as shown in Eq. 26 [13]. In this
simulation we take kdis = 0.00078 day
-1.
DRðtÞ ¼ DRð1Þ þ DRð0Þ  DRð1Þ½   ekdist ð26Þ
Once treatment with glucocorticoids is discontinued after 6 years
(T = 2190 days), the system completely recovers and equilibrates at its original
baseline DR(0). Results from a study in patients with rheumatoid arthritis receiving
low-dose prednisone suggest that this recovery process is relatively fast and occurs
within 1 year [42]. Respective changes in bone cells during (0 \ t B T) and after
(T \ t \?) treatment with glucocorticoids can be computed according to Eq. 27.
DRðtÞ ¼
DRð1Þ þ DRð0Þ  DRð1Þ½   ekdist ð0\t TÞ
DRð0Þ þ DRðTÞ  DRð0Þ½   ekwashðtTÞ ðT\t\1Þ
(
ð27Þ
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Here, T represents the time at which treatment with glucocorticoids was
discontinued and kwash represents the first-order rate constant characterizing the
offset of the glucocorticoid effect.
Software
Simulations were performed in MatLab version R2011a. In light of the stiffness of
the system, the ode-solver ‘‘ode23s’’ was used.
Results
Application of dimensional analysis to the conceptual bone cell interaction model
by Lemaire et al. [13] allowed us to evaluate (i) the relative importance of its model
terms, (ii) the relative speeds of the processes involved, and (iii) the critical
dimensionless numbers (often combinations of parameters), which determine the
qualitative character of the dynamics of the system. In particular, we were able to
show mathematically that responding osteoblasts (R) rapidly reach a quasi-steady
state with active osteoclasts (C) for the model parameters provided in [13]. Thus,
for R and C the quasi-steady state assumption was shown to hold and the original
three-dimensional system containing R, B, and C could be reduced to a simpler,
two-dimensional system, whose dynamics is determined by B and C. Reduction to a
two-dimensional system further allowed for a graphical representation of its
dynamics in the planar State Space. While the state of the system can be depicted as
a point in the state space, its evolution is characterized by a respective curve
parameterized by the time t (the orbit, cf. Fig. 9 in Appendix B). Representation in
the state space also enables a transparent discussion of the system’s dynamics and
readily reveals qualitative properties, such as the absence of overshoot and rebound.
When evaluating the performance of both the full Lemaire model and the reduced
model following rapid interventions, such as a sudden decrease or increase in
estrogen levels (Appendix B), our findings show that the dynamic properties of both
models are very similar but not identical (Fig. 8 in Appendix B). Small
discrepancies between the dynamic properties of the two models exist during the
first 10–20 days after the rapid intervention. Once the speed of the onset and/or
offset of these interventions decreases to more (patho)physiological/therapeutic
levels, the profiles of both models become more and more similar. On the time scale
of disease progression and therapeutic intervention both the full Lemaire model and
the mathematically reduced model show negligible differences in their ability to
characterizing the dynamic interaction between osteoclasts and osteoblasts.
Estrogen
In particular, results of our first scenario (estrogen deficiency) indicate that once
estrogen levels are declining, their inhibiting effect on bone cell proliferation is
gradually lost, leading to an increased differentiation and activation of both
osteoblasts and osteoclasts. This estrogen-mediated effect is more pronounced for
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C than for R and B resulting in an elevated C/B ratio (high turnover) and thus
increased bone resorption (Fig. 2). On the other hand, the system equilibrates at a
new steady-state upon start of the estrogen replacement therapy (Fig. 3, ‘‘Materials
and methods’’ section), which is different from its original baseline. The
establishment of a new steady-state results in a slow-down or even halt of
osteoporotic processes. It should be noted though that for symptomatic therapeutic
interventions, such as estrogen replacement therapy, the underlying disease is still
progressing at its natural rate [3]. The status of patients having received symptomatic
treatments will consequently be indistinguishable from that of untreated patients
once the treatment has been discontinued and the drug effect has washed out.
Fig. 2 Effect of slowly decreasing endogenous estrogen production on bone turnover. Top panel Impact
on responding osteoblasts (R, red), active osteoblasts (B, blue), and active osteoclasts (C, green); Bottom
panel Impact on the active osteoclasts/osteoblast (C/B) ratio. An increase in the C/B ratio results in bone
loss, whereas a decrease results in bone gain. The solid lines represent the simulated change in bone cells
using the full model, whereas the dashed lines represent the respective changes using the mathematically
reduced model
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Vitamin D
In comparison, changes in Vitamin D exposure have a bigger impact on osteoclasts
than on osteoblasts (Fig. 4). The seasonal nature of these changes leads to a
periodically elevated C/B ratio, which is maximally elevated during the winter when
Vitamin D levels are lowest.
Fig. 3 Effect of estrogen replacement therapy on the dynamics of bone cells (I) prior to the start
of treatment (disease progression due to estrogen deficiency), (II) during treatment, and (III) after
treatment cessation. Top panel Impact on responding osteoblasts (R, red), active osteoblasts (B, blue), and
active osteoclasts (C, green); Bottom panel Impact on the active osteoclasts/osteoblast (C/B) ratio. The
solid lines represent the simulated change in bone cells using the full model, whereas the dashed lines
represent the respective changes using the mathematically reduced model. Treatment starts after
1 year (t = 365 days) and is discontinued after 4 years (t = 1460 days) and is depicted by a black solid
arrow
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Fig. 4 Effect of seasonal changes in Vitamin D exposure on bone turnover. Top panel: Impact on
responding osteoblasts (R, red), active osteoblasts (B, blue), and active osteoclasts (C, green); Middle
panel Impact on responding osteoblasts (R, red), active osteoblasts (B, blue), and active osteoclasts
(C, green) with focus on R and B; Bottom panel Impact on the active osteoclasts/osteoblast (C/B) ratio.
The solid lines represent the simulated change in bone cells using the full model, whereas the dashed lines
represent the respective changes using the mathematically reduced model. The simulation starts at the
highest Vitamin D exposure in the summer and peaks during the winter
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Ageing
Changes in the bone’s TGF-b content due to ageing also result in a rapid
increase of the active osteoclast to active osteoblast ratio as shown in Fig. 5. Our
findings further indicate that these changes in the C/B ratio are non-reversible
and lead to a rapid increase in the breakdown of bone in subjects 65 and
older.
Fig. 5 Effect of ageing on bone turnover. Top panel Impact on responding osteoblasts (R, red), active
osteoblasts (B, blue), and active osteoclasts (C, green); Bottom panel Impact on the active osteoclasts/
osteoblast (C/B) ratio. The solid lines represent the simulated change in bone cells using the full model,
whereas the dashed lines represent the respective changes using the mathematically reduced model
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Glucocorticoids
Finally, simulated profiles for the chronic glucocorticoid treatment scenario
(Fig. 6) show that a drug-mediated decrease of the osteoblast precursor
differentiation has a much bigger effect on the maturation and activation of
osteoblasts than that of osteoclasts. These differences in effect size result in a
rapid increase in the C/B ratio (i.e., high bone turnover) and a subsequent decrease
Fig. 6 Effect of chronic glucocorticoid treatment on bone turnover. Top panel Impact on responding
osteoblasts (R, red), active osteoblasts (B, blue), and active osteoclasts (C, green); Bottom panel Impact
on the active osteoclasts/osteoblast (C/B) ratio. The solid lines represent the simulated change in bone
cells using the full model, whereas the dashed lines represent the respective changes using the
mathematically reduced model
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in bone mass. However, these glucocorticoid-induced site effects are reversible as
the maturation of osteoblast progenitors can recover upon termination drug
treatment (Fig. 7, ‘‘Materials and methods’’ section). The system’s recovery also
results in the reestablishment of the original C/B ratio and subsequently no further
bone loss.
Fig. 7 Effect of glucocorticoid treatment on bone turnover before (I) and after (II) treatment cessation.
Top panel Impact on responding osteoblasts (R, red), active osteoblasts (B, blue), and active osteoclasts
(C, green); Bottom panel Impact on the active osteoclasts/osteoblast ratio (C/B) during treatment/
washout. The solid lines represent the simulated change in bone cells using the full model, whereas the
dashed lines represent the respective changes using the mathematically reduced model. Treatment
with glucocorticoids is discontinued after 6 years (t = 2190 days) and is depicted by a black solid
arrow
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Discussion
The effects of both local and systemic control mechanisms on the regulation of bone
remodeling result in the establishment of a complex framework that contains
multiple spatial and temporal levels. To obtain a sufficient understanding of this
framework, its dynamics, and the impact of therapeutic interventions and disease
processes, the use of mathematical models is required (for a more elaborate
conceptual discussion of the role of mathematical modeling for characterizing bone
turnover see also [43]). Mathematical modeling provides a powerful tool as it allows
incorporation of information from different in vitro and in vivo experiments into a
single approach. Once developed and validated, these models can be used in silico
to explore the cause-effect relationship and to assist the formulation of new
hypotheses as well as the design of new experimental studies. However, as these
frameworks become more complex, problems with identifying the key mechanisms
that cause a system to undergo pathophysiological changes may arise [3, 4]. To
identify these key components, sufficient understanding of a system’s dynamic
properties is often more informative than characterizing its complexity. One way of
exploring a system’s dynamic properties is to mathematically reduce completely
mechanistic models in order to evaluate (1) the relative importance of the various
model components and (2) the relative speed of the processes involved for the
overall performance of the system.
To demonstrate the benefits and limitations of model reduction, we analyzed the
well-known bone-cell interaction model proposed by Lemaire et al. [13], which is
based on the RANK-RANKL-OPG signaling pathway. By performing a dimen-
sional analysis, we identified critical properties, such as overall and relative time
scales, on the basis of the parameter values quoted in [13]. We found that for these
parameter values the dynamics of the responding osteoblasts was relatively fast
compared to that of active osteoblasts and osteoclasts. The dynamics of the system
were thus primarily driven by changes in osteoclasts and active osteoblasts, whilst
responding osteoblasts follow their lead. Although not all of the parameter values
provided in [13] seem to have been previously validated, corresponding model-
predicted bone cell dynamics are in agreement with clinical observations [44],
where rapid changes in bone resorption markers during/after treatment with
conjugated estrogen and/or alendronate are followed by respective changes in bone
formation markers.
Based on these findings, the conceptual bone cell interaction model by Lemaire
et al. [13] could be reduced from a three- to a two-dimensional system. Reducing
the model’s complexity allowed for a transparent discussion of its dynamics and
also opened the way for a geometric, two-dimensional analysis. This approach
added significantly to the transparency of the system as it allowed its representation
in the Phase Plane. Results of this geometric analysis indicate that there can be no
overshoot at onset and no rebound at washout for the reduced model. Given the
proximity of the concentration curves of the reduced and full model this implies that
any overshoot or rebound the full model might exhibit will be very small (cf.
Appendix B).
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When simulating the response of both the full Lemaire model and the
mathematically reduced model to rapid changes, such as a sudden onset/offset of
effect, we showed that there is overall a good match between the two models (cf.
Fig. 8). Small discrepancies in their dynamic properties were only observed during
the first 10–20 days after the onset/offset of the effect. However, once the relative
speeds of the underlying (patho)physiological processes and therapeutic interven-
tions were taken into account, both models were at any time at quasi-equilibrium
(Figs. 2, 3, 4, 5, 6, 7). Consequently, both models can be used interchangeably for
characterizing bone cell dynamics on the time scale of disease progression and
therapeutic intervention. From a data analysis point of view, the use of the simpler
model is advantageous as fewer parameters have to be identified and estimated. This
aspect becomes particularly important for the analysis of clinical data, where
usually only few samples per subject are available. On the other hand, the
development and validation of disease system models heavily depends on current
knowledge about the biological system, the availability of sufficient data on
different spatial/temporal levels, and the availability of appropriate software tools
that allow running and visualizing these models based on widely accepted modeling
standards [4, 45].
The application of advanced mathematical and statistical tools, such as
mathematical model reduction, can guide the development of disease system
models as it allows one to identify the rate-limiting steps within complex, dynamic
systems. The joint use of systems pharmacology and mathematical model reduction
approaches provides, therefore, a powerful combination as it can guide the
identification of drug-, system-, and disease-specific parameters, informative
biomarkers as well as the generation of data, where such information can be
obtained from. In particular, knowledge on the system’s dynamics and the time
scales involved in the establishment of disease and drug effects can guide clinical
trial design as it allows to identifying its maximal susceptibility to changes in the
underlying physiology and/or therapeutic interventions. For example, the response
of the reduced model to a step-decrease in estrogen suggests that in this case a
washout design would be superior to a delayed start design for characterizing the
impact of this physiological change on bone remodeling. This is due to the fact that
in this case equilibrium is reached much faster after washout of the intervention than
following its onset (cf. Appendix B; Figs. 8, 9). These findings are in agreement
with those of Ploeger and Holford, who found a washout design superior to a
delayed start design for characterizing and distinguishing treatment effect types in
Parkinson’s disease [46].
In conclusion, mathematical model reduction is a valuable approach for
analyzing disease systems and simplifying complex models while maintaining
their dynamic properties. A significant decrease in the number of parameters to be
identified and estimated in addition to an increased system transparency qualifies
reduced models as tools to evaluate the impact of changes in physiological states
and/or therapeutic interventions with respect to the different time scales involved.
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Appendix A: Model parameters
From the parameter values provided by Lemaire et al. (Table 1) [13], the fraction of
occupied PTH receptors (pP) can be computed according to Eq. 28:
pP ¼ P þ P
0
P þ Ps ¼ 0:019; P ¼
IP
kP







where P is the amount of externally administered PTH, P0 is the amount of
endogenous produced PTH, which is produced at a rate SP, and P
s is the amount of
PTH at which 50% of the receptors are occupied. The baseline values of a and b are
given by a0 and b0 (cf. Eq. 29).
a0 ¼ k3
k4 þ k3K K
P









Based on these values, we find the following baseline concentrations R0, B0, and
C0 for the full as well as for the reduced system:
R0 ¼ 1:82  104 pM; B0 ¼ 1:58  103 pM; C0 ¼ 3:285  103 pM:
ð30Þ
When the internal PTH production increases (from 250 pM/day to 3765 pM/day)
due to decreased Vitamin D exposure, corresponding values for a and b are given by
a1 and b1:
a1  22274 pM1; b1  1460 pM1; ð31Þ
and the baseline changes accordingly.
Appendix B: Systems analysis
In this paper we have shown that the full Lemaire model and the mathematically
reduced model show negligible differences in their dynamic properties for relatively
slow processes that occur on the time scale of disease progression and/or therapeutic
intervention. In this appendix we compare the performance of the full and the
reduced model on the time scale of very rapid interventions, such as a temporary
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drop in estrogen levels, where onset and offset are instantaneous and have no
dynamics of their own. This sudden drop and equally sudden rebound of estrogen
levels results in a function for b that has the form
bðsÞ ¼ b0IðsÞ ð32Þ
where
IðsÞ ¼ 1 for 0\s\s1 and s [ s2




Thus, the estrogen level drops instantaneously from a normal to a constant,
deficient level at s = s1 and abruptly returns to the normal level at s = s2.
(Throughout this appendix we use the dimensionless variables.)
Although physiologically unrealistic, we choose this form of exposure because it
focuses attention on the dynamics of the two systems we wish to compare and
challenges them maximally because of the sudden changes at onset and offset.
In Fig. 8 we show graphs of the dimensionless concentrations computed with the
full model (drawn; in color) and with the reduced model (dashed; black). Clearly,
the match is very good, even after onset and offset.
It is interesting to note that (i) after onset the concentrations increase
monotonically to their new steady-state values, i.e., there is no overshoot, and
similarly, after washout, they drop monotonically back to baseline without any
Fig. 8 Effect of rapidly changing estrogen concentrations on bone cell dynamics (I) at normal (non-
deficient) estrogen levels, (II) following a step-decrease to a constant, deficient estrogen level, and (III)
following a step-increase back to normal (non-deficient) estrogen levels. Solid red lines represent
simulated changes in responding osteoblasts (x), solid blue lines those in active osteoblasts (y), and solid
green lines those in active osteoclasts (z) based on the full model, whereas dashed lines represent the
respective changes based on the mathematically reduced model. The duration of the step-change is
depicted by a black solid arrow. Note that the time t can be computed as t = s/kb
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rebound, and (ii) after onset, the time to equilibrium is much longer than after
washout.
To understand how this comes about, we turn to a geometric analysis of the
reduced system, which we restate below
dy
ds
¼ rðzÞ  y
dz
ds









Because this system consists of only two equations involving the concentrations y
and z, we can describe its dynamics by following the state of the system (y,z) as a
point in the (y,z)-plane, also called the Phase Plane, as it moves with time [47].
In the phase plane one can identify two useful curves, the Null Clines Uy and Uz,
along which dy/ds = 0 and dz/ds = 0, respectively. We readily see from (34) that
the null clines are given by:
Cy : y ¼ rðzÞ ð35Þ
the blue curve in Fig. 9 and, depending on whether the value of b is normal
(I(s) = 1) or decreased (I(s) = 1-Imax),




Fig. 9 Orbit of the reduced system (34) (in red) in the (z,y)-plane. At normal estrogen levels, the system
is at baseline (y,z) = (1,1), which is characterized by the intersection point of the solid blue line (Uy) and
the solid green line (Uz (normal)). Once estrogen levels change, Uz changes and the system starts moving
towards a new steady-state (yss,zss). In case of a sudden drop in estrogen levels, realized here by a step-
decrease in b, yss,zss is now determined by the intersection point of Uy and the new Null Cline
Uz(decreased) (dashed green line). As a result, the system starts moving from (1,1) towards (yss,zss). Once
estrogen concentrations return to their baseline levels, the system moves back to its original baseline (1,1)
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Cdz : y ¼ zrðzÞ
1 þ b0ð1  ImaxÞR0r2ðzÞ
1 þ b0R0
decreased
the green curves in Fig. 9 (Cnz solid and C
d
z dashed).




z , both dy/ds = 0 and dz/
ds = 0, so that such a point is an equilibrium point. When I(s) = 1, the null clines
Uy and C
n
z intersect at the point (y,z) = (1,1), the baseline. We see that when b is
decreased Uy and the new null cline C
d
z still intersect, but now at the point (yss,zss)
and that yss [ 1 and zss [ 1.
At each point in the (y,z)-plane we can read off from the system of Eq. 34 the
values of dy/ds and dz/ds and hence the direction of the orbit. Thus, we see that the
orbit leaves the baseline point (1,1) in a horizontal direction and thereafter moves up
and towards the right. We also see that it cannot cross Uy and the new C
d
z so that it
must move towards the new equilibrium point (yss,zss). Thus, both y(t) and z(t) are
increasing and hence there is no overshoot. Similarly, at washout the orbit leaves
(yss,zss) in a horizontal direction, moving down and to the left. Again, y(t) and
z(t) are monotone and there is no rebound.
Appendix C Transformation of (18) into (19)
In this appendix we show how the system (18) expressed in terms of dimensionless




; y ¼ B
B0
; z ¼ C
C0
; s ¼ kBt ð37Þ
The first equation of (18): When converting the original variables R, B, and C in





¼ B0kB rðzÞ  B
B0
 
¼ B0kBrðzÞ  kBB ð38Þ
where r(z) = pz(z)/pz(1). Note that
pzðzÞ ¼ z þ f0z
s
z þ zs ¼
C þ f0Cs
C þ Cs ¼ pCðCÞ
and
pzð1Þ ¼ 1 þ f0z
s
1 þ zs ¼
C0 þ f0Cs
C0 þ Cs ¼ pCðC0Þ
Thus, Eq. 39 can be written as
dB
dt
¼ B0kB pCðCÞpCðC0Þ  kBB ð39Þ
By definition, the baseline values B0 and C0 are related through the equation
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DRpCðC0Þ  kBB0 ¼ 0
When we use this expression in (39) we obtain
dB
dt
¼ DRpCðCÞ  kBB; ð40Þ
which establishes the first equation of (19).





¼ C0kB  DA
kB
























By definition, the baseline values B0 and C0 are related through the equation
DC
aB0












1 þ bR  DApCðCÞC ð43Þ
Finally, since








and R0 and C0 are related through the equation






we can write (44) as
R ¼ RðCÞ ¼def DB
DR
p2CðCÞ ð45Þ
This completes the transformation of the two equations of the system (18) into
those of the system (19).
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